Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma

Medicine and Dentistry

• Therapeutic Procedure 100%
• Non-Hodgkin Lymphoma 100%
• B-Cell Chronic Lymphocytic Leukemia 100%
• B Cell 100%
• Rituximab 100%
• Bendamustine 100%
• Multiple Myeloma 17%
• Benzimidazole 17%
• Purine 13%
• Combination Therapy 8%
• Toxicity 8%
• Patient 8%
• Drug 8%
• Chemotherapeutic Agent 8%
• Clinical Study 8%
• Adverse Event 8%
• Progression Free Survival 8%
• Interim Analysis 8%
• Parent 4%
• In Vitro 4%
• Alkylating Antineoplastic Agent 4%
• Breast Cancer 4%
• Pharmacodynamics 4%
• Hematologic Malignancy 4%
• Cancer 4%
• Inpatient 4%
• Infection 4%
• Arm 4%
• Assay 4%
• Amino Acid 4%
• Chlormethine 4%
• Hematology 4%
• Spontaneous Remission 4%
• Monotherapy 4%
• Fatigue 4%
• Bioavailability 4%
• Fever 4%
• Active Metabolite 4%
• Isoprenaline 4%
• Progressive Disease 4%
• First Pass Effect 4%
• Xerostomia 4%
• Clinical Oncology 4%
• Hodgkin's Lymphoma 4%
• Cross Resistance 4%
• Nausea 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Nonhodgkin Lymphoma 100%
• Chronic Lymphatic Leukemia 100%
• Rituximab 100%
• Bendamustine 100%
• Multiple Myeloma 17%
• Benzimidazole 17%
• Chlorambucil 17%
• Chlormethine Derivative 13%
• Toxicity 8%
• Drug 8%
• Progression Free Survival 8%
• Adverse Event 8%
• Purine 8%
• Diseases 4%
• Alkylating Agent 4%
• Breast Cancer 4%
• Nitrogen Mustard 4%
• Infection 4%
• Monotherapy 4%
• Pharmacodynamics 4%
• Glycine 4%
• Remission 4%
• Fatigue 4%
• Fever 4%
• Bioavailability 4%
• Nausea 4%
• Isoprenaline 4%
• Active Metabolite 4%
• Hematologic Malignancy 4%
• CYP1A2 4%
• Cross-Resistance 4%
• Hodgkin Disease 4%
• Xerostomia 4%
• Purine Derivative 4%